Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trialResearch in context by Hans-Kittil Viermyr, Kristian Tonby, Erica Ponzi, Sophie Trouillet-Assant, Julien Poissy, José R. Arribas, Virginie Dyon-Tafani, Maude Bouscambert-Duchamp, Lambert Assoumou, Bente Halvorsen, Nuriye Basdag Tekin, Alpha Diallo, Lucie De Gastines, Ludvig A. Munthe, Sarah Louise Murphy, Thor Ueland, Annika E. Michelsen, Fridtjof Lund-Johansen, Pål Aukrust, Joy Mootien, Benjamin Dervieux, Yoann Zerbib, Jean-Christophe Richard, Renaud Prével, Denis Malvy, Jean-François Timsit, Nathan Peiffer-Smadja, Damien Roux, Lionel Piroth, Hafid Ait-Oufella, Cesar Vieira, Olav Dalgard, Lars Heggelund, Karl Erik Müller, Jannicke Horjen Møller, Anders Benjamin Kildal, Vegard Skogen, Saad Aballi, Jonas Daniel Sjøberg Øgaard, Anne Ma Dyrhol-Riise, Anders Tveita, Amin Alirezaylavasani, Dominique Costagliola, Yazdan Yazdanpanah, Inge Christoffer Olsen, Tuva Børresdatter Dahl, Hassen Kared, Aleksander Rygh Holten, Marius Trøseid

Get full text